

## DAFTAR PUSTAKA

- [ABCSG] Anglian Breast Cancer Study Group. 2000. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. *Br J Cancer*. 83:1301-8.
- Andreoli TE. 2010. *Andreoli and Carpenter's Cecil Essentials of Medicine*. 8th ed. Philadelphia: Elsevier. hlm. 593–628
- American Cancer Society. 2015. Breast cancer facts & figures 2015-2016. Atlanta: American Cancer Society Inc.
- Anothaisintawee, T., C. Wiratkapun., P. Lerdsitthichai, V. Kasamesup., S. Wongwaisayawan, and J. Srinakarin. 2013. Risk factors of breast cancer: a systematic review and meta-analysis. *Asia Pac J Public Health*. 25: 368-87.
- Aryandono T., Harijadi, Soeripto. 2006. Hormone Receptor status operable Breast Cancer in Indonesia : Correlation with other prognostic factors and survival, *Journal of Cancer Prevantion*. 7: 21-324
- Balman, J., O. Diez., I. Rubio. And M. Castiglione. 2010. BRCA in breast cancer: ESMO clinical practice guidelines. *Ann Oncol*. 21: 20-22.
- Bedognetti D, Sertoli RM and Pronzato P. 2011. Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer : A Multicentre Randomized Phase III Trial. *JNCI*. (103)20: 1529-1539.
- Brewster, A.M., G.N. Hortobagyi. and K.R. Broglio. 2008. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy. *Journal of The National Cancer Institute*. 100: 1179-1183.
- Brunton, L.L., C. Bruce. and K., Bojorn Knollman. (ed). 2011. *Goodman and Gilman's The Pharmacological Basic of Therapeutics*. Twelfth edition. New York : The McGraw- Hill Companies, Inc. 1382-1388.
- Burstein, H.J., A.A Prestrud, and J. Seidenfeld. 2014. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. *J Clin Oncol*. (28)23:3784-96.

- Carey, I.A., C.N. Perou. and C.A. Livasy. 2006. Race Breast Cancer Subtype and Survival In the Caroline. BC Study (J) JAMA. 295(21) : 2942-2502.
- Cianfrocca. M. and Goldstein. L.J., Prognostic and Predictive Factors in Early-Stage Breast Cancer, *The oncologist J*, 2004.
- Clark, GM (2000). Prognostic and Predictive Factors. In: Harris JR, Lippmann ME, Morrow M, Osborne CK (eds). *Diseases of the Breast*. 2nd ed, Lippincott, Williams & Wilkins, Philadelphia : 489-514.
- Coates, A.S., E.P. Winer., A. Goldhirsch., R.D. Gelber., M. Gnant., M.P. Gebhart. *et al.* 2015. Improving The Management of Early Breast Cancer: St. Gallen International Expert Consensus On The Primary Therapy of Early Breast Cancer 2015. European Society For Medical Oncology. *Ann Oncol.* 1-38.
- Collaborative Group on Hormon Factors in Breast Cancer, 2012. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118964 women with breast cancer from 117 epidemiological studies. *Lancet Oncol.* 13: 1141–51.
- Cui, J., Y. Shen. and R. Li. .2012. Estrogen Synthesis and Signaling Pathways during aging: From Periphery to brain. Elsevier. 19: 197-209
- Cuzick, J., I. Sestak., M. Baum., A. Buzdar., A. Howell., M. Dowsett. and J.F. Forbes. 2010. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. *Lancet Oncology.* (11)12:1135–1141.
- Dahabreh, J. Issa., L. Helen., S. Fotios., F. George. and M. Samuel. 2008. Trastuzumab in the Adjuvant treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *The Oncologist.* 13:620-630.
- Dananjaya, R. 2017. Hubungan golongan obat antihormonal dengan ES pada pasien kanker payudara stadium dini di kota Padang tahun 2016. [skripsi]. Pp 1-76
- Desai SB, Moonim MT, Gill AK et al ( 2000). Hormone receptor status of breast cancer in India: a study of 798 tumours. *The Breast.* 9 :267-70.
- Devita, V.T., T.S. Lawrence. and S.A. Rosenberg. 2008. *Cancer Principle's & Practice of Oncology.* Eight edition. Philadelphia: Lippincott William and Wilkins. 1603-1604.
- DiPiro, J.T. and B.G. Wells. 2015. *Pharmacotherapy handbook: A Patophysiologic Approach.* Ninth edition. New York: McGraw-Hill Education.

Dellapasqu, S., M. Colleoni., R. Gelber. and A. Goldhirsch. 2005. Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer, American Society of Clinical Oncology. J Clin Oncol. 23:1736-1750.

Dowsett, M., J.F. Forbes., J. Bradley., A. Ingle and T. Aihara. 2015. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Lancet Oncology. (386)10001:1341-1352.

[EBCOG] Early Breast Cancer Overview Group. 2007. Use of Luteinising Hormone Releasing Hormone Agonist as Adjuvant Treatment in Premenopausal Patients with hormone receptor positive breast cancer: a meta analysis of individual patient from randomised adjuvant trials. Lancet. 369: 1711-1723.

[EBCTCG] Early Breast Cancer Trialists Collaborative Group. 2011. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378:771-784.

Edge, S.B., D.R. Byrd. and C.C. Compton. 2010. AJCC Cancer Staging Manual. 7th ed. New York. Springer. 347-76.

Fang, L., Z. Barekari., B. Zhang., Z. Liu. and X. Zhong. 2011. Targeted Therapy in Breast Cancer: What's New? European J of Med Sci.

Feitelson, M.A., A. Arzumanyan., R.J. Kulathinal., S.W. Blain., R.F. Holcombe. And J. Mahajna and Marino., M. 2015. Sustained Proliferation in Cancer: Mechanism and Novel Therapeutic Targets. Journal of Hand Surgery. 35: 25-54.

Freedman, O.C., G.G. Fletcher., S. Gandhi, M. Mates., S.F. Dent., M.E. Trudeau and members of the Early Breast Cancer Systemic Therapy Consensus Panel. 2015. Adjuvant endocrine therapy for early breast cancer : a systematic review of the evidence for 2014 Cancer Care Ontario systemic therapy guideline. Current Oncology. (22)1: 95-113.

Fora, A. 2017. Tesis. Analisis Survival Pasien Kanker Payudara Usia Muda Kota Padang Tahun 2011-2016 [Tesis]. Padang. Universitas Andalas Padang 132 hal.

Gnant, M. 2011. Zolendronic acid in breast cancer : Latest findings and Interpretation. Med. Oncol. 3: 293-301.

Gennari, A., M.P. Sormani. and P. Prozanto .2008. HER2 Status and Efficacy of Adjuvant Anthracyclin in Early Breast Cancer: A pooled Analysis of Randomized Trials. J Natl Cancer Inst. 100: 14-20.



GLOBOCAN, WHO. 2018 Estimated cancer incidence, mortality and prevalence worldwide in 2012. [http://globocan.iarc.fr/pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/pages/fact_sheets_cancer.aspx). [diakses pada 15september 2018].

Goldhirsch A and Winer E.P. A. Goldhirsch, E. P. Winer, A. S. Coates, R. D. Gelber, M. Piccart-Gebhart, B. Thürlimann, H. J. Senn, Kathy S. Albain, 2013. Personalizing The Treatment of Women With EBC; Expert Consensus of The Primary Therapy of EBC. *Ann Oncology*.

Gray RG, Rea D, and Handley K. 2013. ATTom: Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. *J Clin Oncol* 31. 18(5).

Gu, Ran., Weijuan, Jia., Yunjie, Zeng., Nanyan, Rao., Yue, Hu. And Shunrong, Li. A comparison of Survival outcomes and Side Effect of TMX Therapy in Premenopausal Estrogen and Progesteron (+) Breast Cancer, 2012.

Guyton, A.C. and J.E. Hall, 2007. *Textbook of Medical Physiology* 11<sup>th</sup> Ed. Diterjemahkan oleh Irawati Setiawan dkk; *Buku Ajar Fisiologi Kedokteran* (Edisi 11). Jakarta: Penerbit Buku Kedokteran EGC.

Hackshaw, Allan., Baum, M., Fornander, T., Nordenskjöld B., Nicolucci, A., Monson, K., Forsyth, S., *et al.* 2009. Long term effectiveness of adjuvant Goserelin in Premenopausal women with Early Breast Cancer. *J Natl cancer Inst*; 101:341-349.

Harvey, J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol*. 1999;17:1474-81.

Hoffmann, M., Pinho, H., Cooper, D.J., Sayed, R., Dent, M.D., Gudgeon, A. *et al.* 2000. BC Incidence and Determinants of Cancer Stage In The Western Cape. *Afr Med J*. 90 (12): 1212-1216.

Irwan, Azamris, Bachtiar H. 2015. Perbandingan Prognosis Subtipe Molekuler Kanker Payudara Antara Pasien Kanker Payudara. *Majalah Kedokteran Andalas*. 38(3):208-217.

John, E.N., O.A. James., H.D. James., B.K. Michael. and E.T. Joel . 2014. *Abeloffs Clinical Oncology* 5<sup>th</sup> Ed. New York. *J Clin Oncol*. Inc. 1753-1791

Kabel A.M and Baali F.H, Breast Cancer: Insights into Risk Factors, Pathogenesis, Diagnosis and Management. *Journal of Cancer Research and Treatment* Vol. 3, No. 2, 2015, pp 28-33. 2015

Katz, V.L., G.M. Lentz., R.A. Lobo. and D.M. Gershenson. 2007. Katz: Comprehensive Gynecology 5<sup>th</sup> Ed. New York: The Elsevier Inc. 298-324.

Katzung, B., S.B. Masters. and T.A. Trevor. 2014. Farmakologi Dasar Dan Klinik edisi 12.

Kementerian Kesehatan. 2015. Panduan Nasional Penanganan Kanker Payudara.

Khambri, D. 2015. Peran Terapi Hormonal pada kanker Payudara. *Majalah Kedokteran Andalas*. 38(1): 64-65.

Kobayashi, S., H. Sugiura., Y. Ando., N. Shiraki., T. Yanagi. and H. Yamashita. 2012. Reproductive history and breast cancer risk. *Breast Cancer*. 19: 302-308.

Kumar, V., K.A. Abdul. and C.A. Jon. 2013. Robbins basic Pathology. Philadelphia. The Elsevier Inc. 19: 681-771.

Lakhani, S.R., Ellis. I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J. WHO classifications of tumors. Ed 4<sup>th</sup>. IARC. 2012.

Lonning, P., P.Christian., A.Martoni. and C. Zamagni. 2003 Pharmacokinetics of Third-Generation Aromatase Inhibitor. *Seminars in Oncology*. (30) 14: 23-32.

Lucille, R.M . 2012. Integrative medicine. New York: Saunders. 692-696.

Lullmann, H., K. Mohr., Mohr K. and Hein L. 2017. *Color Atlas of Pharmacology*. Fifth edition. New York: Thieme Stuttgart. 444p

Mauri, D., N. Paylidis., N.P. Polyzos. and J.P. Ioannidis. 2006. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. *Journal of the National Cancer Institute*. (98)18:1285–1291.

McGee, E.A. and J.F. Strauss. 2016. Endocrinology: Adult dan Pediatric. New York: Elsevier Inc. 2192-2206.

McGuire, A., J.A. Brown., C. R. Malone., M.J. McLaughlin. and M.J. Kerin. 2015. Effects of age on the detection and management of breast cancer. *2*: 908–29.

McPherson, K.C., M. Steel. and J. M. Dixon. 2000. Breast cancer—epidemiology, risk factors, and genetics. *BMJ*. 321(7261): 624–628.

Megawati, Gambaran ketahanan hidup lima tahun pasien kanker payudara berdasarkan karakteristik demografi dan faktor klinis di rumah sakit Ciptomangunkusumo tahun 2007-2010. Jakarta, Universitas Indonesia. 2011. Pp:35-39.

Moore KL, Dalley AF. 2013. *Anatomi Berorientasi Klinis Jilid 1*. Edisi ke-5. Jakarta: Penerbit Erlangga. hlm. 105–12.

Mouridsen, H., M. Gershanovich. and Sun Y. 2003. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. *Journal of Clinical Oncology*.(21)11:2101–2109.

[NCCN] The National Comprehensive Cancer Network Guideline. 2016. Guideline for Patient Breast Cancer Stage I and II.

Nelson, H.D., B. Zakher., A. Cantor., J. Griffin and E.S. O'Meara. 2012. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. *Ann Intern Med*. 156: 635-48.

Notoatmodjo. 2010. Ilmu Perilaku Kesehatan. Jakarta. Rineka Cipta.

Osborne, M.P. and S.K. Bool Bol. 2014. *Breast Anatomy and Development*. In Harris RJ, Lippman ME, Morrow M, Osborne KC, editors. *Diseases of the Breast* 5th Ed. Philadelphia: Wolters Kluwer Health. 3-14.

Osborne, C.K., H. Zhao. and S.A. Fuqua. 2000. Selective Estrogen Receptors Modulators: Structure, Function and Clinical Use. *J. Clin Oncol*. 18: 3172-3186.

Osborne, C.K. and R. Schiff. 2011. Mechanisms of Endocrine Resistance in Breast Cancer. *Annual Review of Medicine*. 62:233-247.

Payne, S.J.L., R.L. Bowen., J.L. Jones. and C.A. Wells. 2008. Predictive markers in Breast Cancer. *Histopathology*.(52)1: 82-90.

Polyak, K. Heterogeneity in Breast Cancer. *J of Clinical Investigation*. 2011; 121(10): 86-3788.

Purwanto, H., H. Djoko, H. Samuel, H.W. Arif Ed., 2014. PERABOI: Panduan Penatalaksanaan Kanker Payudara 2014. 155 hal.

[Pusdatin] Pusat Data dan Informasi Kementerian Kesehatan RI. 2015. Situasi Penyakit kanker. Buletin Jendela Data dan Informasi Kesehatan.



- Ramli, M. 2015. Update Breast Cancer management Diagnostic and Treatment. *Majalah Kedokteran Andalas*.(38)1:1-26.<http://jurnalmka.fk.unand.ac.id>. [diakses pada 27 februari 2018].
- Rianti E, Tirtawati GA, Novita H. Faktor-faktor yang berhubungan dengan kanker payudara wanita. *J.Heal Qual*, 2012 ; 3 (1): 10-23
- Regan, M.M., P. Neven and A.G. Hurder. 2011. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. *Lancet Oncology*(12)12:1101–1108.
- Romera, J., T.J. Lao. and H. Puertolas. 2011. Update On Adjuvant Hormon Treatment of Early Breast Cancer. *Springer Health Care*. (28)6:1-18.
- Rukminingsih, F., A. T. Murti., R. Fita. dan W. Kartika. 2017. Evaluasi Terapi Adjuvan dan Kejadian Relaps Pada Pasien *Premenopousal Early Breast Cancer* di RSUP DR. Sardjito Yogyakarta. *Jurnal Manajemen dan Pelayanan Farmasi*. 6: 25-30.
- Sainsbury, R. 2013. The development of endocrine therapy for women with breastcancer, Princess Anne Hospital, Southampton University Hospitals Foundation NHS Trust. Southampton, UK. 39:507-517.
- Senkus, E., S.Kyriakides., P. Llorca., P.Portmans., A.Thompson., S. Zackrisson *et al*. 2015. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and Follow up. *Ann of Oncology*.
- {SEER} Surveillance, Epidemiology, and End Results. 2014. <http://seer.cancer.gov/>. [diakses pada 25 Februari 2018].
- Shrigondekar P, Desail S, Bhosale S., Deepti Mankar, Anuya Badwe. 2011. Study of Hormone Receptor Status of Breast Carcinoma and Its Correlation with the Established Prognostic Markers. *International Journal of Health Sciences and Research*.1(2):109-116.
- Sagita Silvia. 2013. Analisis Hubungan Tingkat Pendidikan Pasien dengan Kanker Payudara Stadium Dini di Instalasi Rawat Inap RSCM Jakarta Tahun 2012. [Skripsi]. Fakultas Kesehatan Masyarakat. Universitas Indonesia.
- Soerjomataram I., Louwman M.W.J., Ribot J.G., Roukema J.A., Coebergh J.W.W. 2008.An overview of prognostic factors for long-term survivors of breast cancer. *Breast Cancer Res Treat*. 107:309–330.
- Syahratul Aeni, Ketahanan hidup pasien kanker payudara di RSUP dr. Wahidin Sudiro Husodo, Makassar, 2014.

- Shier D, Butler J, Lewis R. 2012. *Hole's Essentials of Anatomy and Physiology*. 11th ed. New York: McGraw Hill. hlm. 525–6.
- Sjamsuhidajat R, de Jong W. 2013. *Buku Ajar Ilmu Bedah*. Edisi ke-3. Jakarta: EGC. hlm. 471–496.
- Torre A.L, Bray F, Siegel RL, Ferlay J, Lortet J., Jemal A., Global Cancer Statistics, 2012. *CA A Cancer J Clin* [Internet]. 2015;65(2):87–108. Available from: <http://onlinelibrary.wiley.com/doi/10.3322/caac.21262/full>
- Untch, M.C. and C. Thomssen. 2010. Clinical practice decisions in endocrine therapy. *Cancer Investigation*. 28 :4–13.
- Van D.P, Buerger H., Kuijper A, Van D. Wall E. Breast Carcinogenesis. In: Kuerer H, editor. *Kuerer's Breast Surgical Oncology*. New York: McGraw-Hill; 2010. p. 3–152.
- Wei, R., Lau S.S. and Cheung P.S. 2010. Breast carcinoma In Chinese women, does ages affect treatment choice and outcome?. *Asian J.Surg*.33: 97-102.
- Yao, C., Liu Y., Huang H. and Zhang J. 2010. Correlation between clinicopathological features and postoperative prognosis in patient with breast cancer. *Int J Clin Exp Med*. 11(3) : 2483-2488.
- Yu, Z., Guo, X., jiang, Y., Teng, L., Luo, J. 2017. Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone receptor positive : a systemic review and network meta analysis. *Breast cancer*.25: 8-16.
- Zilli M., A. Grassadonia., N. Tinari., A.D. Giacobbe., S. Gildetti., J. Giampietro. and C. Natoli. 2009. Molecular Mechanism Of Endocrine Resistance and Their Implication in the Therapy of Breast Cancer. *J endocrin*. 175:62-81.